BACKGROUND: The natural history of adult liver disease due to α1-antitrypsin deficiency (A1AD) remains poorly understood. OBJECTIVE: We investigated whether heterozygosity for the Z-allele predisposes for the development of clinically significant portal hypertension (CSPH). Moreover, we aimed to non-invasively assess the prevalence of liver fibrosis and hepatic steatosis in adults with A1AD treated by pulmonologists. METHODS: SERPINA1 rs28929474 (Z-allele) was genotyped in 315 patients with CSPH (hepatic venous pressure gradient ≥10 mmHg; cases) and 248 liver donors (controls). In addition, 31 adults with A1AD (Pi*ZZ/Pi*SZ) and 11 first-degree relatives (Pi*MZ/Pi*MS) underwent liver stiffness and controlled attenuation parameter (CAP) measurement. RESULTS: Heterozygosity for the Z-allele was observed in 6.7% of patients with CSPH and 2.8% of liver donors. Thus, harboring the Z-allele was associated with increased odds of CSPH (odds ratio: 2.47; 95% confidence interval: 1.03-5.9; P = 0.042). Among Pi*ZZ/Pi*SZ patients, 23%/3% had liver stiffness values indicative of liver fibrosis ( ≥F2/ ≥F3). Interestingly, 65%/52% of Pi*ZZ/Pi*SZ patients had CAP values indicative of hepatic steatosis ( ≥S1/ ≥S2). CONCLUSIONS: Heterozygosity for the Z-allele predisposes for the development of CSPH, confirming its role as a genetic (co)factor in liver disease. Pi*ZZ/SZ patients rarely develop liver fibrosis ≥F3 during adulthood; however, liver fibrosis ≥F2 is common. Elevated CAP values hint at underlying hepatic steatosis, which might promote liver fibrosis progression.
BACKGROUND: The natural history of adult liver disease due to α1-antitrypsin deficiency (A1AD) remains poorly understood. OBJECTIVE: We investigated whether heterozygosity for the Z-allele predisposes for the development of clinically significant portal hypertension (CSPH). Moreover, we aimed to non-invasively assess the prevalence of liver fibrosis and hepatic steatosis in adults with A1AD treated by pulmonologists. METHODS: SERPINA1 rs28929474 (Z-allele) was genotyped in 315 patients with CSPH (hepatic venous pressure gradient ≥10 mmHg; cases) and 248 liver donors (controls). In addition, 31 adults with A1AD (Pi*ZZ/Pi*SZ) and 11 first-degree relatives (Pi*MZ/Pi*MS) underwent liver stiffness and controlled attenuation parameter (CAP) measurement. RESULTS: Heterozygosity for the Z-allele was observed in 6.7% of patients with CSPH and 2.8% of liver donors. Thus, harboring the Z-allele was associated with increased odds of CSPH (odds ratio: 2.47; 95% confidence interval: 1.03-5.9; P = 0.042). Among Pi*ZZ/Pi*SZ patients, 23%/3% had liver stiffness values indicative of liver fibrosis ( ≥F2/ ≥F3). Interestingly, 65%/52% of Pi*ZZ/Pi*SZ patients had CAP values indicative of hepatic steatosis ( ≥S1/ ≥S2). CONCLUSIONS: Heterozygosity for the Z-allele predisposes for the development of CSPH, confirming its role as a genetic (co)factor in liver disease. Pi*ZZ/SZ patients rarely develop liver fibrosis ≥F3 during adulthood; however, liver fibrosis ≥F2 is common. Elevated CAP values hint at underlying hepatic steatosis, which might promote liver fibrosis progression.
Authors: Philipp Schwabl; Simona Bota; Petra Salzl; Mattias Mandorfer; Berit A Payer; Arnulf Ferlitsch; Judith Stift; Friedrich Wrba; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger Journal: Liver Int Date: 2014-07-09 Impact factor: 5.828
Authors: R G Kim; P Nguyen; R Bettencourt; P S Dulai; W Haufe; J Hooker; J Minocha; M A Valasek; H Aryafar; D A Brenner; C B Sirlin; R Loomba Journal: Aliment Pharmacol Ther Date: 2016-06-09 Impact factor: 8.171
Authors: Simona Bota; Harald Herkner; Ioan Sporea; Petra Salzl; Roxana Sirli; Adriana M Neghina; Markus Peck-Radosavljevic Journal: Liver Int Date: 2013-07-16 Impact factor: 5.828
Authors: Tessa M Cacciottolo; William T H Gelson; Gerald Maguire; Susan E Davies; William J H Griffiths Journal: Eur J Gastroenterol Hepatol Date: 2014-04 Impact factor: 2.566
Authors: Aaron Hakim; Matthew Moll; Dandi Qiao; Jiangyuan Liu; Jessica A Lasky-Su; Edwin K Silverman; Silvia Vilarinho; Z Gordon Jiang; Brian D Hobbs; Michael H Cho Journal: Hepatol Commun Date: 2021-04-03
Authors: Gerard N McElvaney; Robert A Sandhaus; Marc Miravitlles; Gerard M Turino; Niels Seersholm; Marion Wencker; Robert A Stockley Journal: Eur Respir J Date: 2020-06-18 Impact factor: 16.671
Authors: Georg Semmler; Lorenz Balcar; Hannes Oberkofler; Stephan Zandanell; Michael Strasser; David Niederseer; Alexandra Feldman; Felix Stickel; Pavel Strnad; Christian Datz; Bernhard Paulweber; Elmar Aigner Journal: J Pers Med Date: 2021-03-01
Authors: Bernhard Scheiner; Albert F Stättermayer; Philipp Schwabl; Theresa Bucsics; Rafael Paternostro; David Bauer; Benedikt Simbrunner; Ralf Schmidt; Rodrig Marculescu; Arnulf Ferlitsch; Markus Peck-Radosavljevic; Mathias Pinter; Michael Trauner; Thomas Reiberger; Peter Ferenci; Mattias Mandorfer Journal: Liver Int Date: 2019-12-03 Impact factor: 5.828